Computational analysis of image‐based drug profiling predicts synergistic drug combinations: Applications in triple‐negative breast cancer

[1]  R. M. Simpson,et al.  TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms , 2014, Molecular oncology.

[2]  Dan L. Longo Bruce A. Chabner.  Cancer chemotherapy and biotherapy , 2013 .

[3]  Luke A. Gilbert,et al.  Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.

[4]  Oliver Rath,et al.  Kinesins and cancer , 2012, Nature Reviews Cancer.

[5]  I. Burney.  Cancer Chemotherapy and Biotherapy : Principles and Practice , 2011 .

[6]  Chih-Jen Lin,et al.  LIBSVM: A library for support vector machines , 2011, TIST.

[7]  E. Pasquier,et al.  ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties , 2010, Molecular Cancer Therapeutics.

[8]  W. Kuo,et al.  Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer , 2010, Clinical Cancer Research.

[9]  T. Peretz,et al.  Mitomycin C and Vinblastine: An Active Regimen in Previously Treated Breast Cancer Patients , 2009, Tumori.

[10]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[11]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[12]  Li Mao,et al.  Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells , 2022 .

[13]  Xiaobo Zhou,et al.  An image score inference system for RNAi genome-wide screening based on fuzzy mixture regression modeling , 2009, J. Biomed. Informatics.

[14]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[15]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[16]  R. Sun,et al.  Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm , 2008, Proceedings of the National Academy of Sciences.

[17]  Jacob D. Feala,et al.  Search Algorithms as a Framework for the Optimization of Drug Combinations , 2008, PLoS Comput. Biol..

[18]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Pasquier,et al.  Microtubules: A dynamic target in cancer therapy , 2008, IUBMB life.

[20]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[21]  Makoto Kinoshita,et al.  [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[22]  Scott E. Fraser,et al.  Imaging in Systems Biology , 2007, Cell.

[23]  L. Mayer,et al.  Optimizing combination chemotherapy by controlling drug ratios. , 2007, Molecular interventions.

[24]  Sridhar Ramaswamy,et al.  Rational design of cancer-drug combinations. , 2007, The New England journal of medicine.

[25]  Stephen T. C. Wong,et al.  An automated feedback system with the hybrid model of scoring and classification for solving over‐segmentation problems in RNAi high content screening , 2007, Journal of microscopy.

[26]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[27]  Lani F. Wu,et al.  Image-based multivariate profiling of drug responses from single cells , 2007, Nature Methods.

[28]  I. Ohishi,et al.  Disassembly of actin filaments by botulinum C2 toxin and actin‐filament‐disrupting agents induces assembly of microtubules in human leukaemia cell lines , 2007, Biology of the cell.

[29]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[30]  Jeffrey R. Jackson,et al.  Targeted anti-mitotic therapies: can we improve on tubulin agents? , 2007, Nature Reviews Cancer.

[31]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[32]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Dancey,et al.  Strategies for optimizing combinations of molecularly targeted anticancer agents , 2006, Nature Reviews Drug Discovery.

[34]  Lit-Hsin Loo,et al.  Automated multivariate profiling of drug effects from fluorescence microscopy images , 2006, 3rd IEEE International Symposium on Biomedical Imaging: Nano to Macro, 2006..

[35]  T. Mayer,et al.  Synthesis and Biological Evaluation of Novel Eg5 Inhibitors , 2005, Chembiochem : a European journal of chemical biology.

[36]  I. Vernos,et al.  Development and Biological Evaluation of Potent and Specific Inhibitors of Mitotic Kinesin Eg5 , 2005, Chembiochem : a European journal of chemical biology.

[37]  M. Piccart,et al.  Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer , 2005 .

[38]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[39]  M. Elkabets,et al.  Differential effects of monastrol in two human cell lines , 2004, Cellular and Molecular Life Sciences CMLS.

[40]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[41]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Kerr,et al.  Anticancer drug development , 2002 .

[43]  B. Hill,et al.  Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. , 2001, Molecular pharmacology.

[44]  B. Garvik,et al.  Principles for the Buffering of Genetic Variation , 2001, Science.

[45]  T. Enomoto,et al.  Microtubule disruption induces the formation of actin stress fibers and focal adhesions in cultured cells: possible involvement of the rho signal cascade. , 1996, Cell structure and function.

[46]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[47]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[48]  S. Mathoulin-Pélissier,et al.  How valid are claims for synergy in published clinical studies ? , 2022 .